专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

71. 发明申请

WO9530018A3 RECOMBINANT POXVIRUSES WITH FOREIGN POLYNUCLEOTIDES IN ESSENTIAL REGIONS 审中-公开
标题翻译：具有特殊区域的外来多核苷酸的重组病毒
公开(公告)号：WO9530018A3
公开(公告)日：1996-01-04
申请号：PCT/EP9501629
申请日：1995-04-28
申请人： IMMUNO AG , FALKNER FALKO GUENTER , HOLZER GEORG , DORNER FRIEDRICH
发明人： FALKNER FALKO-GUENTER , HOLZER GEORG , DORNER FRIEDRICH
IPC分类号： A01K67/027 , A61K39/00 , C07K14/07 , C07K14/16 , C12N5/10 , C12N7/00 , C12N7/01 , C12N15/09 , C12N15/39 , C12N15/863 , C12R1/92 , C12N15/86 , A01K67/00 , C12N15/16 , C12N15/63
CPC分类号： C12N15/86 , A01K2217/05 , A61K39/00 , C07K14/005 , C12N2710/24122 , C12N2710/24143 , C12N2740/16222 , C12N2830/00 , C12N2830/002 , C12N2830/15 , C12N2830/42 , C12N2830/55 , C12N2830/60 , C12N2840/203
摘要： Defective poxviruses that lack a function imparted by an essential region of its parental poxvirus can be employed for protein production and vaccination, among other uses. A polynucleotide encoding the protein to be produced by the recombinant virus is inserted into the defective poxvirus and placed under transcriptional control of a promoter. The defective poxvirus is viable when the lost function of the essential region is complemented by a host cell, transgenic animal or helper virus.

72. 发明申请

WO9532298A2 SAFE VECTORS FOR GENE THERAPY 审中-公开
标题翻译：安全感染基因治疗方案
公开(公告)号：WO9532298A2
公开(公告)日：1995-11-30
申请号：PCT/US9506176
申请日：1995-05-16
申请人： RES CORP TECHNOLOGIES INC
发明人： PATHAK VINAY K , HU WEI-SHAU
IPC分类号： C12N15/09 , A61K31/70 , A61K35/76 , A61K38/00 , A61K38/22 , A61K38/43 , A61K48/00 , A61P7/06 , A61P9/10 , A61P31/12 , A61P43/00 , C07H21/04 , C12N5/00 , C12N5/10 , C12N7/00 , C12N15/867 , C12R1/91 , C12R1/92 , C12N15/86 , C07K14/005 , C12N7/04
CPC分类号： C12N15/86 , A61K48/00 , C12N2740/13043 , C12N2840/203
摘要： The present invention provides retroviral vectors comprising direct repeats flanking a sequence that is desired to be deleted upon reverse transcription in a host cell. In a preferred embodiment the sequence that is desired to be deleted is the retroviral cis-acting encapsidation sequence (E) essential for virus production in helper cells. In gene therapy embodiments, the E sequence is deleted upon reverse transcription in target cells, thus preventing spread of retroviral vectors to non-target cells in the event of infection with replication competent viruses. The retroviral vectors of the present invention thus provide safe vectors for gene therapy.
摘要翻译：本发明提供了逆转录病毒载体，其包含在宿主细胞中逆转录时期望被缺失的序列侧翼的直接重复。在一个优选的实施方案中，期望缺失的序列是辅助细胞中病毒产生所必需的逆转录病毒顺式作用的壳化序列（E）。在基因疗法实施方案中，在靶细胞中逆转录后，E序列被缺失，从而防止在复制有感染性病毒感染的情况下将逆转录病毒载体扩散到非靶细胞。因此，本发明的逆转录病毒载体提供了用于基因治疗的安全载体。

73. 发明申请

WO9516048A3 RECOMBINANT PROTEIN PRODUCTION IN BOVINE ADENOVIRUS EXPRESSION VECTOR SYSTEM 审中-公开
标题翻译：牛血清型表达载体系统中重组蛋白的生产
公开(公告)号：WO9516048A3
公开(公告)日：1995-09-28
申请号：PCT/CA9400678
申请日：1994-12-09
申请人： UNIV SASKATCHEWAN
发明人： MITTAL SURESH K , GRAHAM FRANK L , PREVEC LUDVIK , BABIUK LORNE A
IPC分类号： A61K48/00 , C07K14/075 , C12N7/01 , C12N15/861 , C12N15/86 , C12N5/10 , C12R1/92
CPC分类号： C12N15/86 , A61K48/00 , C07K14/005 , C12N2710/10322 , C12N2710/10343 , C12N2710/10352
摘要： The present invention relates to novel live bovine adenovirus (BAV) expression vector systems in which part or all of one or both of the early region 1 (E1) and early region 3 (E3) genes are deleted and replaced by a foreign gene or fragment thereof and novel recombinant mammalian cell lines stably transformed with BAV E1 sequences, and therefore, express E1 gene products capable of allowing replication therein of a bovine adenovirus having an E1 deletion replaced by a heterologous nucleotide sequence encoding a foreign gene or fragment thereof and their use in production of (antigenic) polypeptides or fragments thereof for the purpose of live recombinant virus or subunit vaccine or for other therapies.

74. 发明申请

WO9300365A3 HEPATITIS C VIRUS (HCV) POLYPEPTIDES 审中-公开
标题翻译：丙型肝炎病毒（HCV）多肽
公开(公告)号：WO9300365A3
公开(公告)日：1993-04-29
申请号：PCT/US9205388
申请日：1992-06-24
申请人： CHIRON CORP
发明人： CHIEN DAVID Y , RUTTER WILLIAM
IPC分类号： A61K39/29 , A61K39/00 , A61K39/395 , A61P31/12 , A61P31/14 , A61P31/18 , C07K1/04 , C07K1/06 , C07K4/02 , C07K7/06 , C07K7/08 , C07K14/005 , C07K14/18 , C07K16/00 , C07K16/08 , C12N7/00 , C12N15/09 , C12P21/02 , C12P21/08 , C12R1/92 , G01N33/53 , G01N33/543 , G01N33/569 , G01N33/576 , C07K15/04 , C07K7/10
CPC分类号： C07K14/005 , A61K39/00 , C12N2770/24222
摘要： HCV epitopes useful as immunogenic reagents, and corresponding antibodies and methods of use are disclosed.

75. 发明申请

WO9106658A3 INFECTIVE PROTEIN DELIVERY SYSTEM 审中-公开
标题翻译：感染性蛋白质递送系统
公开(公告)号：WO9106658A3
公开(公告)日：1991-10-17
申请号：PCT/US9006141
申请日：1990-10-23
申请人： CETUS CORP
发明人： KRIEGLER MICHAEL , PEREZ CARL F
IPC分类号： C12N5/10 , A01N63/00 , A61K9/50 , A61K35/76 , A61K38/00 , A61K38/19 , A61K38/21 , A61K38/22 , A61K48/00 , A61P35/00 , C07K14/47 , C07K14/525 , C07K14/57 , C12N5/08 , C12N5/22 , C12N7/00 , C12N15/09 , C12N15/19 , C12N15/23 , C12N15/28 , C12N15/48 , C12N15/867 , C12P21/02 , C12R1/91 , C12R1/92 , C12N15/86 , A61K37/02 , A61K47/00 , C07K13/00 , C12N15/62
CPC分类号： A61K9/5184 , A61K38/191 , A61K38/21 , C07K14/525 , C07K14/57 , C07K2319/02 , C12N15/86 , C12N2740/13043 , C12N2740/13052 , Y10S930/144 , A61K2300/00
摘要： A virion expression system for a desired protein packaged in an envelope derived from a retrovirus useful in administering proteins which cross cell membranes in order to serve their function. Preferred virions are those that carry an RNA sequence that encodes cytokines or lymphokines, and includes IL-2, multiple drug resistance protein, and TNF.

76. 发明申请

WO9002803A3 VIRAL VACCINES 审中-公开
标题翻译：病毒疫苗
公开(公告)号：WO9002803A3
公开(公告)日：1990-05-31
申请号：PCT/GB8901076
申请日：1989-09-13
申请人： RHONE MERIEUX
发明人： ROSS LOUIS JOSEPH NORMAN , SCOTT SIMON DAVID , BINNS MATTHEW MCKINLEY
IPC分类号： A01K67/027 , A61K31/00 , A61K35/76 , A61K38/00 , A61K39/00 , A61K39/12 , A61K39/215 , A61K39/245 , A61K39/255 , A61K39/265 , A61K39/275 , A61K39/295 , A61K48/00 , A61P31/00 , A61P31/12 , A61P31/20 , A61P31/22 , A61P37/04 , C07K14/00 , C07K14/005 , C07K14/03 , C07K14/035 , C07K14/055 , C07K14/195 , C12N20060101 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N7/00 , C12N7/01 , C12N7/04 , C12N9/02 , C12N9/12 , C12N15/00 , C12N15/09 , C12N15/33 , C12N15/38 , C12N15/45 , C12N15/86 , C12N15/869 , C12P21/02 , C12R1/91 , C12R1/92
CPC分类号： C12N15/86 , A61K38/00 , A61K39/00 , A61K39/12 , A61K39/245 , A61K39/255 , A61K2039/51 , A61K2039/5254 , A61K2039/5256 , C07K14/005 , C12N9/0093 , C12N9/1211 , C12N15/00 , C12N2710/16022 , C12N2710/16034 , C12N2710/16043 , C12N2710/16322 , C12N2710/16334 , C12N2710/16343
摘要： A vaccine effective against Marek's disease virus (MDV) comprises (a) an MDV attenuated by virtue of being TK- or (b) a host expressing an MDV antigen, namely the respective MDV homologues of the HSV gB, gC, gD or gH glycoproteins (or antigenic parts thereof) or the respective MDV homologues of the HSV-1 immediate early genes IE-68 or IE-175. The host may be a herpes virus of turkeys (HVT), more particularly HVT in which the MDV antigen is inserted in the HVT homologue of the HSV gC gene, the ribonucleotide reductase (large subunit) gene or the thymidine kinase (TK) gene.

77. 发明申请

WO2019157231A3 BACTERIOPHAGE FOR TREATMENT AND PREVENTION OF BACTERIA-ASSOCIATED CANCERS 审中-公开
公开(公告)号：WO2019157231A3
公开(公告)日：2019-08-15
申请号：PCT/US2019/017129
申请日：2019-02-07
申请人： ARMATA PHARMACEUTICALS, INC.
发明人： MORALES, Sandra, P. , BILINSKY, Igor, P.
IPC分类号： A61K35/76 , A61K35/768 , A61K45/06 , A61P31/04 , C12N1/06 , C12N7/01 , C12N7/02 , C12R1/92
摘要： The present invention relates to a bacteriophage composition comprising one or more (suitably two or more, or three) bacteriophages that target oncogenic (tumorigenic) bacteria, and use of the same for treating or preventing cancer.

78. 发明申请

WO2015073682A1 METHODS OF DETECTING CELLS LATENTLY INFECTED WITH HIV 审中-公开
标题翻译：检测感染艾滋病毒的细胞的方法
公开(公告)号：WO2015073682A1
公开(公告)日：2015-05-21
申请号：PCT/US2014/065472
申请日：2014-11-13
申请人： OREGON HEALTH AND SCIENCE UNIVERSITY
发明人： FROMENTIN, Remi , CHOMONT, Nicolas , SEKALY, Rafick-pierre
IPC分类号： G01N33/569 , C12N1/06 , C12N7/04 , C12R1/92
CPC分类号： G01N33/56988 , G01N33/505 , G01N33/56972 , G01N2333/70514 , G01N2333/70596 , G01N2500/10
摘要： Disclosed are methods of detecting and isolating CD4+ T cells latently infected with HIV as well as methods of screening for inhibitors of CD4 + T cells latently infected with HIV.
摘要翻译：公开了检测和分离潜伏感染HIV的CD4 + T细胞的方法以及筛选HIV潜伏感染的CD4 + T细胞抑制剂的方法。

79. 发明申请

WO2012021308A3 METHOD FOR RETROVIRUS REMOVAL 审中-公开
标题翻译：去除血管病毒的方法
公开(公告)号：WO2012021308A3
公开(公告)日：2012-06-14
申请号：PCT/US2011045905
申请日：2011-07-29
申请人： EMD MILLIPORE CORP , KAS ONUR Y , KOZLOV MIKHAIL , TKACIK GABRIEL , MOYA WILSON , GODDARD PHILIP , LEON SHERRY , HAO JIBIN
发明人： KAS ONUR Y , KOZLOV MIKHAIL , TKACIK GABRIEL , MOYA WILSON , GODDARD PHILIP , LEON SHERRY , HAO JIBIN
IPC分类号： C12Q1/70 , C12M1/12 , C12Q1/24 , C12R1/92
CPC分类号： B01D39/1623 , A61L2/022 , B01D39/00 , B01D39/04 , B01D39/14 , B01D39/16 , B01D39/1607 , B01D39/1615 , B01D39/18 , B01D61/14 , B01D67/0004 , B01D67/002 , B01D69/02 , B01D69/10 , B01D2239/0208 , B01D2239/0216 , B01D2239/025 , B01D2239/0442 , B01D2239/0631 , B01D2239/10 , B01D2239/1233 , B01D2323/39 , B01D2323/42 , B01D2325/20 , C12N7/00 , C12N2740/16051 , D01D1/02 , D01D5/0092 , D01F6/96 , D10B2505/04
摘要： A method for removing retroviruses from liquid samples and a nanofiber containing liquid filtration medium that simultaneously exhibits high liquid permeability and high microorganism intention is disclosed. Retroviruses are removed from a liquid by passing the liquid through a porous nanofiber containing filtration medium having a retrovirus LRV greater than about 6, and the nanofiber(s) has a diameter from about 10 nm to about 100 nm. The filtration medium can be in the form of a fibrous electrospun polymeric nanofiber liquid filtration medium mat.
摘要翻译：公开了一种从液体样品中除去逆转录病毒的方法和含有液体过滤介质的纳米纤维，同时具有高液体渗透性和高微生物意图。通过使液体通过含有大于约6的逆转录病毒LRV的过滤介质的多孔纳米纤维从液体中除去逆转录病毒，并且纳米纤维的直径为约10nm至约100nm。过滤介质可以是纤维电纺聚合物纳米纤维液体过滤介质垫的形式。

80. 发明申请

WO2011137445A2 SALIVA POLYMERASE CHAIN REACTION ASSAY FOR CYTOMEGALOVIRUS INFECTION 审中-公开
标题翻译：用于细胞病毒感染的SALIVA聚合酶链反应测定
公开(公告)号：WO2011137445A2
公开(公告)日：2011-11-03
申请号：PCT/US2011/034809
申请日：2011-05-02
申请人： The UAB Research Foundation , BOPPANA, Suresh , NOVAK, Zdenek , ROSS, Shannon
发明人： BOPPANA, Suresh , NOVAK, Zdenek , ROSS, Shannon
IPC分类号： C12Q1/70 , C12Q1/68 , C12N15/38 , C12R1/92
CPC分类号： C12Q1/705 , C12Q2600/16 , C12Q2537/143 , C12Q2531/113
摘要： Congenital cytomegalovirus (CMV) infection is an important cause of disease in infants and immune-compromised adults. Most infants infected with CMV are not promptly identified because of the absence of symptoms. It has been discovered that an assay based on the polymerase chain reaction (PCR) for testing of saliva specimens for CMV is rapid, accurate, and inexpensive. Some versions of the assay employ primers that are specific for sequences flanking the highly conserved major envelope glycoprotein B or the highly conserved immediate early 2 exon 5 genes. The assay exceeds the standard rapid culture technique in accuracy, speed, and economy. When the assay is performed on dried saliva, it loses no significant amount of accuracy, and is surprisingly much more sensitive than a PCR assay using dried blood. This assay will permit broader testing to detect and intervene in congenital CMV infection, potentially avoiding numerous cases of associated disease.
摘要翻译：先天性巨细胞病毒（CMV）感染是婴幼儿和免疫受损成年人疾病的重要原因。感染CMV的大多数婴儿由于没有症状而没有及时发现。已经发现，基于用于测试CMV的唾液样本的聚合酶链反应（PCR）的测定是快速，准确和便宜的。该测定的一些版本使用对高度保守的主要包膜糖蛋白B或高度保守的即时早期2外显子5基因侧翼的序列特异性的引物。该测定超过了准确度，速度和经济性的标准快速培养技术。当在干燥的唾液上进行测定时，其不会显着的准确度，并且比使用干燥血液的PCR测定更令人惊奇地更加敏感。该测定将允许更广泛的测试来检测和介入先天性CMV感染，可能避免许多相关疾病的病例。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式